{"id":58287,"date":"2024-06-05T08:00:00","date_gmt":"2024-06-05T06:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-presente-de-nouvelles-donnees-sur-lefficacite-a-long-terme-delafibranor-et-la-qualite-de-vie-liee-aux-demangeaisons-chez-les-patients-atteints-de-cholangite-biliaire-primitive\/"},"modified":"2024-07-23T10:24:00","modified_gmt":"2024-07-23T08:24:00","slug":"ipsen-presente-de-nouvelles-donnees-sur-lefficacite-a-long-terme-delafibranor-et-la-qualite-de-vie-liee-aux-demangeaisons-chez-les-patients-atteints-de-cholangite-biliaire-primitive","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-presente-de-nouvelles-donnees-sur-lefficacite-a-long-terme-delafibranor-et-la-qualite-de-vie-liee-aux-demangeaisons-chez-les-patients-atteints-de-cholangite-biliaire-primitive\/","title":{"rendered":"Ipsen pr\u00e9sente de nouvelles donn\u00e9es sur l\u2019efficacit\u00e9 \u00e0 long terme d\u2019elafibranor et la qualit\u00e9 de vie li\u00e9e aux d\u00e9mangeaisons chez les patients atteints de cholangite biliaire primitive"},"content":{"rendered":"\n